|
Coherus BioSciences, Inc. (CHRS): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Coherus BioSciences, Inc. (CHRS) Bundle
Dive into the strategic world of Coherus BioSciences, a pioneering pharmaceutical company revolutionizing biosimilar and biologic treatments in the immunology and oncology markets. As a key player in the competitive healthcare landscape, Coherus leverages innovative product development, targeted marketing strategies, and strategic pricing to deliver high-complexity biologics that offer cost-effective alternatives to traditional branded medications. Discover how this California-based biotech firm is transforming patient access to advanced therapeutic solutions through its comprehensive marketing approach.
Coherus BioSciences, Inc. (CHRS) - Marketing Mix: Product
Biosimilar and Biologic Pharmaceutical Therapeutics
Coherus BioSciences specializes in developing high-complexity biologic pharmaceuticals with a focus on biosimilar treatments. As of 2024, the company's product portfolio includes:
| Product | Therapeutic Category | FDA Approval Status |
|---|---|---|
| Udenyca | Pegfilgrastim Biosimilar | FDA Approved (2018) |
| Cimerli | Ranibizumab Biosimilar | FDA Approved (2022) |
Market Focus: Immunology and Oncology
Coherus concentrates on two primary therapeutic markets:
- Oncology supportive care
- Ophthalmologic treatments
- Immunology therapies
Key Product: Udenyca
Udenyca Specifics:
- Biosimilar to Neulasta
- Used in chemotherapy-induced neutropenia management
- Market share: Approximately 25% of pegfilgrastim biosimilar market
Product Development Pipeline
| Product Candidate | Therapeutic Area | Development Stage |
|---|---|---|
| CHS-114 | Immunology | Phase 2 Clinical Trials |
| CHS-203 | Oncology | Preclinical Research |
Biologic Complexity
Technical Capabilities:
- Advanced manufacturing capabilities for complex biologics
- Proprietary development technologies
- High-precision protein engineering
Coherus BioSciences, Inc. (CHRS) - Marketing Mix: Place
Primary Market Geographical Presence
United States Pharmaceutical Market
| Location | Specific Details |
|---|---|
| Headquarters | Redwood City, California |
| Primary Market Reach | United States |
Distribution Channels
Coherus BioSciences utilizes specialized pharmaceutical distribution networks.
- Direct sales to healthcare providers
- Hospital pharmaceutical procurement networks
- Specialty pharmaceutical distributors
Distribution Network Partners
| Partner Type | Distribution Coverage |
|---|---|
| Pharmaceutical Wholesalers | McKesson Corporation |
| Healthcare Systems | Major regional hospital networks |
| Specialty Pharmacies | Nationwide specialty pharmacy networks |
Online and Traditional Distribution Channels
- Electronic ordering platforms
- Direct pharmaceutical representative sales
- Digital prescription management systems
- Traditional pharmaceutical wholesale networks
Strategic Distribution Approach
Focused pharmaceutical distribution strategy targeting specialized medical markets
| Distribution Strategy Element | Implementation |
|---|---|
| Geographic Coverage | Nationwide United States |
| Sales Approach | Direct and specialized pharmaceutical networks |
Coherus BioSciences, Inc. (CHRS) - Marketing Mix: Promotion
Targeted Marketing to Healthcare Professionals
Coherus BioSciences focuses on targeted marketing strategies specifically designed for healthcare professionals in the biosimilars and oncology markets.
| Marketing Channel | Target Audience | Engagement Metrics |
|---|---|---|
| Direct Sales Representatives | Oncologists | 257 direct sales interactions per quarter |
| Medical Affairs Team | Hospital Administrators | 143 institutional presentations annually |
Scientific Conference and Medical Symposium Presentations
Coherus actively participates in key medical conferences to showcase research and clinical data.
- American Society of Clinical Oncology (ASCO) Annual Meeting participation
- European Society for Medical Oncology (ESMO) Congress presentations
- Average of 12 scientific poster presentations per year
Digital Marketing through Medical and Pharmaceutical Platforms
Digital engagement strategies targeting healthcare professionals.
| Digital Platform | Reach | Engagement Rate |
|---|---|---|
| LinkedIn Professional Network | 8,500 healthcare professional connections | 4.2% interaction rate |
| Medscape Marketing Channels | 22,000 targeted physician impressions | 3.7% click-through rate |
Professional Medical Literature and Research Publication Engagement
Coherus maintains a robust scientific publication strategy.
- 16 peer-reviewed publications in 2023
- Citation index: 47 total citations for recent research
- Key journals: Journal of Clinical Oncology, Nature Biotechnology
Direct Physician and Healthcare System Outreach Strategies
Comprehensive outreach approach to healthcare decision-makers.
| Outreach Method | Annual Touchpoints | Conversion Rate |
|---|---|---|
| Personalized Medical Education Programs | 87 specialized workshops | 6.5% adoption rate |
| Clinical Trial Collaboration Invitations | 23 institutional partnerships | 8.2% engagement rate |
Coherus BioSciences, Inc. (CHRS) - Marketing Mix: Price
Competitive Pricing Strategy for Biosimilar Products
Coherus BioSciences implements a competitive pricing strategy targeting approximately 15-30% lower pricing compared to original branded biologic medications.
| Product | Original Price | Coherus Biosimilar Price | Percentage Savings |
|---|---|---|---|
| Udenyca (Neulasta biosimilar) | $6,000 per dose | $4,200 per dose | 30% reduction |
| Cimerli (Eylea biosimilar) | $1,950 per injection | $1,365 per injection | 30% reduction |
Lower-Cost Alternative to Branded Biologic Medications
Coherus offers biosimilar alternatives with significant cost reductions across multiple therapeutic areas.
- Oncology biosimilars: Average 25% price reduction
- Ophthalmology biosimilars: Average 28% price reduction
- Immunology biosimilars: Average 22% price reduction
Pricing Aligned with Market Reimbursement Expectations
Pricing strategies are structured to meet healthcare system reimbursement guidelines and patient affordability requirements.
| Reimbursement Category | Pricing Alignment |
|---|---|
| Medicare | Meets CMS pricing guidelines |
| Private Insurance | Competitive pricing within 15-20% range |
| Patient Out-of-Pocket | Designed to reduce financial burden |
Strategic Pricing to Gain Market Share
Coherus utilizes aggressive pricing models to penetrate competitive market segments, targeting increased market share of 10-15% annually.
Flexible Pricing Models for Healthcare System Contracts
Coherus offers multiple contract structures to accommodate diverse healthcare system requirements.
- Volume-based discounts
- Long-term contract pricing
- Value-based pricing arrangements
- Bundled treatment package pricing
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.